Targeting Myeloid-derived Suppressor Cells and Programmed Death Ligand 1 Confers Therapeutic Advantage of Ablative Hypofractionated Radiation Therapy Compared With Conventional Fractionated Radiation Therapy
- 1 May 2018
- journal article
- research article
- Published by Elsevier in International Journal of Radiation Oncology - Biology - Physics (IJROBP)
- Vol. 101 (1) , 74-87
Abstract
No abstract availableKeywords
This publication has 34 references indexed in Scilit:
- Myeloid cells are required for PD-1/PD-L1 checkpoint activation and the establishment of an immunosuppressive environment in pancreatic cancerGut, 2016
- Combination of stereotactic ablative body radiation with targeted therapiesThe Lancet Oncology, 2014
- Stereotactic Body Radiation Therapy for Inoperable Early Stage Lung CancerJAMA, 2010
- Arginine regulation by myeloid derived suppressor cells and tolerance in cancer: mechanisms and therapeutic perspectivesImmunological Reviews, 2008
- Local Radiation Therapy of B16 Melanoma Tumors Increases the Generation of Tumor Antigen-Specific Effector Cells That Traffic to the TumorThe Journal of Immunology, 2005
- Tumor Response to Radiotherapy Regulated by Endothelial Cell ApoptosisScience, 2003
- Vascular Endothelial Growth Factor Inhibits the Development of Dendritic Cells and Dramatically Affects the Differentiation of Multiple Hematopoietic Lineages In VivoBlood, 1998
- Radiotherapy Alone for Medically Inoperable Stage I Non-Small–Cell Lung Cancer: The Duke ExperienceInternational Journal of Radiation Oncology - Biology - Physics (IJROBP), 1998
- Radiation therapy alone for stage I non-small cell lung cancerInternational Journal of Radiation Oncology - Biology - Physics (IJROBP), 1993
- An interesting case of possible abscopal effect in malignant melanomaBritish Journal of Radiology, 1975